Overview
Overview
Speakers
Speaker
sciextext
text-left
Discover dedicated analytical solutions that will let you develop a path toward better mRNA-LNP-based therapeutics and vaccines.
Tune in to industry experts explaining how to move beyond analytical boundaries. Learn how to achieve more relevant information on in vitro transcribed (IVT) RNA and lipid nanoparticles (LNPs) for the next generation of therapeutics and vaccines.
registerform
Watch the webinars
one-column
1200pixel
Speakers
Speakers
Addressing stability challenges of mRNA-lipid nanoparticle therapies with formulation development
Jingtao Zhang, PhD and Daniel Turner
Scientific Director, Associate Scientist,
Catalent
Beyond mRNA - how advances in analytical techniques are enabling a revolution of the RNA drug landscape
Andrew Geall, PhD
Chief Development Officer and Co-Founder, Replicate Bioscience
Assessment of distinct mRNA-LNP formulations by multi-capillary gel electrophoresis (CGE-LIF) and implications for RNA-based drugs
Jeremie Parot, PhD
Research Scientist, SINTEF
Adducts and N-oxides: Understanding lipid nanoparticles (LNPs) for better mRNA-based drugs
Adam Crowe, PhD
Manager Analytical Development, Precision NanoSystems ULC
Better mRNA-LNPs: encapsulation efficiency, mRNA integrity and purity, lipid N-oxides and beyond
Jane Luo, PhD
Senior Scientist, SCIEX